Drugs in Dev. Pulmonary/Respiratory Diseases
Phase I
Japan 
Lead Product(s) : AEVI-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Cerecor
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
Details : CERC-002 is a first-in-class anti-LIGHT monoclonal antibody. LIGHT is homologous to lymphotoxin and exhibits an inducible expression. It competes with the HSV glycoprotein D for binding to the herpesvirus entry mediator, a receptor expressed on T lymphoc...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 29, 2021
Lead Product(s) : AEVI-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Cerecor
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : TRK-250
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2018
Lead Product(s) : TRK-250
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
